[go: up one dir, main page]

WO2004015089A3 - Formulations d'acide organique polyionique - Google Patents

Formulations d'acide organique polyionique Download PDF

Info

Publication number
WO2004015089A3
WO2004015089A3 PCT/US2003/025419 US0325419W WO2004015089A3 WO 2004015089 A3 WO2004015089 A3 WO 2004015089A3 US 0325419 W US0325419 W US 0325419W WO 2004015089 A3 WO2004015089 A3 WO 2004015089A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
organic acid
polyionic organic
acid formulations
polyionic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/025419
Other languages
English (en)
Other versions
WO2004015089A2 (fr
Inventor
Michael J Bennett
Yen-Ju Chen
Edmund J Niedzinski
Hsien Tseng
Sean Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genteric Inc
Original Assignee
Genteric Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genteric Inc filed Critical Genteric Inc
Priority to AU2003265432A priority Critical patent/AU2003265432A1/en
Publication of WO2004015089A2 publication Critical patent/WO2004015089A2/fr
Publication of WO2004015089A3 publication Critical patent/WO2004015089A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition de transfection d'acide nucléique comprenant un acide organique polyionique et un acide nucléique. De préférence, l'acide organique polyionique est un colorant. L'invention se rapporte également à des procédés efficaces permettant d'administrer lesdites compositions, d'augmenter l'efficacité de la transfection dans une cellule (p.ex., une cellule de glande sécrétoire), et d'utiliser lesdites compositions comme stabilisateurs de l'acide nucléique afin d'empêcher la dégradation in vivo et in vitro de l'acide nucléique, augmentant de la sorte la demi-vie et la durée de conservation d'un acide nucléique.
PCT/US2003/025419 2002-08-12 2003-08-12 Formulations d'acide organique polyionique Ceased WO2004015089A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003265432A AU2003265432A1 (en) 2002-08-12 2003-08-12 Polyionic organic acid formulations

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US40281102P 2002-08-12 2002-08-12
US60/402,811 2002-08-12
US45399903P 2003-03-11 2003-03-11
US60/453,999 2003-03-11
US47614503P 2003-06-04 2003-06-04
US60/476,145 2003-06-04

Publications (2)

Publication Number Publication Date
WO2004015089A2 WO2004015089A2 (fr) 2004-02-19
WO2004015089A3 true WO2004015089A3 (fr) 2004-07-15

Family

ID=31721505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/025419 Ceased WO2004015089A2 (fr) 2002-08-12 2003-08-12 Formulations d'acide organique polyionique

Country Status (2)

Country Link
AU (1) AU2003265432A1 (fr)
WO (1) WO2004015089A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888107B2 (en) 2006-07-24 2011-02-15 Nanosphere, Inc. System using self-contained processing module for detecting nucleic acids
US7625746B2 (en) 2006-07-24 2009-12-01 Nanosphere, Inc. Method of denaturing and fragmenting DNA or RNA using ultrasound
CZ301561B6 (cs) * 2007-12-04 2010-04-14 Výzkumný ústav živocišné výroby, v. v. i. Prostredek pro prevenci a potlacování kokcidióz
JP7770096B2 (ja) 2016-10-14 2025-11-14 ザ チルドレンズ メディカル センター コーポレーション 中枢神経系の疾患および障害を処置するための組成物および方法
CA3050690A1 (fr) 2017-01-17 2018-07-26 Dana-Farber Cancer Institute, Inc. Compositions et methodes de diagnostic et de traitement des maladies peroxysomales
US11548936B2 (en) 2017-01-17 2023-01-10 Children's Medical Center Corporation Compositions and methods for treating lysosomal storage diseases and disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932539A (en) * 1996-10-15 1999-08-03 The Board Of Trustees Of The University Of Illinois Biodegradable polymer matrix for tissue repair
US20010036925A1 (en) * 1995-03-24 2001-11-01 Michael German Gene therapy by secretory gland expression
US6372722B1 (en) * 2000-01-19 2002-04-16 Genteric, Inc. Method for nucleic acid transfection of cells
US20020108132A1 (en) * 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010036925A1 (en) * 1995-03-24 2001-11-01 Michael German Gene therapy by secretory gland expression
US5932539A (en) * 1996-10-15 1999-08-03 The Board Of Trustees Of The University Of Illinois Biodegradable polymer matrix for tissue repair
US6372722B1 (en) * 2000-01-19 2002-04-16 Genteric, Inc. Method for nucleic acid transfection of cells
US20020108132A1 (en) * 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken

Also Published As

Publication number Publication date
WO2004015089A2 (fr) 2004-02-19
AU2003265432A8 (en) 2004-02-25
AU2003265432A1 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
WO2002074969A3 (fr) Regions se liant a la matrice nucleaire (mar) et procedes d'utilisation de celles-ci
DK0977874T3 (da) Svækket salmonella-stamme anvendt som bæremedium til oral immunisering
AR025683A1 (es) Composiciones de d-endotoxina de bacillus thuringiensis activas contra lepidopteros y metodos de uso
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
AR023229A1 (es) Polipéptidos mutantes, y su uso en composiciones detergentes.
AU8023898A (en) Combined product associating a nucleic acid with a substance breaking up the extracellular matrix for gene therapy
AU4981101A (en) Subtilisin variants
WO2004038378A3 (fr) Colorants a base de phtalocyanine
DK1210411T3 (da) Sammensætninger og fremgangsmåder til forbedret celledyrkning
DE60036537D1 (de) Zusammensetzungen zur gentherapie von diabetes
WO2005016264A3 (fr) Derives de diamines de quinone et leurs utilisations
DK1675954T3 (da) Nukleinsyrer anvendelige til at udløse tumorcelledødelighed
WO2005017098A3 (fr) Compositions et methodes utilisant un arnsi, des composes amphipathiques et des polycations
DE502004003219D1 (de) Hochverzweigte polycarbonate und copolycarbonate mit verbesserter fliessf higkeit, ihre herstellung und verwendung
WO2004015089A3 (fr) Formulations d'acide organique polyionique
WO2007110628A3 (fr) Construction
NO20072998L (no) Stabilisering av glukokortikoidestere med syrer
DK1526840T3 (da) Nanopartikler til DNA administration til et målorgan
WO2003070905A3 (fr) Procedes d'electroporation pour introduire des agents bioactifs dans des cellules
WO2005079532A3 (fr) Procedes et compositions destines a renforcer l'activite du risc in vitro et in vivo
AR017368A1 (es) Un procedimiento para la insercion de adn foraneo en una celula hospedante, un vector recombinante utilizado en dicho procedimiento y el uso del mismo
HK1040402A1 (zh) 使用乳粘素(lactadherin)或其變體的的方法及其組合物
MX2007008980A (es) Acidos nucleicos para apoptosis de celulas cancerigenas.
WO2006055931A3 (fr) Vecteurs pour expression genique stable
WO2004071443A3 (fr) Methodes et compositions de modulation de cellules souches

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP